Results 11 to 20 of about 2,071 (176)

Bimekizumab for the treatment of psoriatic arthritis

Expert Review of Clinical Immunology, 2023
Interleukin (IL)-17A and IL-17F have overlapping roles in pro-inflammatory signaling and have been implicated in the pathogenesis of psoriatic disease. Bimekizumab is the first human monoclonal antibody to selectively inhibit IL-17F in addition to IL-17A.
Yoshiya Tanaka, Stevan Shaw
openaire   +3 more sources

Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials [PDF]

Pain and Therapy
Introduction Pain is a debilitating symptom of hidradenitis suppurativa (HS). Bimekizumab, a humanized IgG1 monoclonal antibody, selectively inhibits IL-17A and IL-17F.
John R. Ingram, Hideki Fujita, Alice B. Gottlieb, Hadar Lev-Tov, Errol Prens, Christopher J. Sayed, Vivian Y. Shi, Jacek C. Szepietowski, Kenzo Takahashi, John W. Frew, Jérémy Lambert, Leah Davis, Tae Oh, Robert Rolleri, Marie-Hélène Saintmard, Lauren A. V. Orenstein   +15 more
doaj   +2 more sources

Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II [PDF]

Dermatology and Therapy
Introduction Hidradenitis suppurativa (HS) symptoms (pain, itch, odour and drainage) impair quality of life (QoL). Bimekizumab, a humanised IgG1 monoclonal antibody, selectively inhibits interleukin (IL)-17A and IL-17F.
Vivian Y. Shi, John R. Ingram, Hadar Lev-Tov, Sylke Schneider-Burrus, Seth Forman, Martina L. Porter, Koremasa Hayama, Linnea Thorlacius, Jérémy Lambert, Tom Vaux, Bartosz Lukowski, Robert L. Rolleri, Jacek C. Szepietowski   +12 more
doaj   +2 more sources

Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study

Dermatology and Therapy
Introduction Bimekizumab and brodalumab are characterized by a different mechanism of action if compared to the other anti-interleukin (IL)-17s which target IL-17A.
Luca Potestio, Fabrizio Martora, Flavia Raia, Gioacchino Lucagnano, Claudio Brescia, Ginevra Torta, Matteo Megna   +6 more
doaj   +2 more sources

Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies

RMD Open
Objectives To assess impact of bimekizumab treatment on patient-reported outcomes and health-related quality of life (HRQoL) in patients with active psoriatic arthritis (PsA), using 16-week data from two phase 3 studies.Methods BE OPTIMAL (NCT03895203 ...
Joseph F Merola, Philip J Mease, Dafna D Gladman, M Elaine Husni, Nadine Goldammer, Jason Coarse, William Tillett, Vanessa Taieb, Jeremy Lambert, Barbara Ink   +9 more
doaj   +2 more sources

Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison [PDF]

Rheumatology and Therapy
Introduction A matching-adjusted indirect comparison (MAIC) was conducted to assess the relative efficacy at 52 weeks (Wk52) of bimekizumab 160 mg every 4 weeks (Q4W) and ustekinumab 45 or 90 mg every 12 weeks (Q12W) in patients with psoriatic arthritis (
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Vanessa Taieb, Jason Eells, Iain B. McInnes   +7 more
doaj   +2 more sources

Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison [PDF]

Rheumatology and Therapy
Introduction The relative efficacy of bimekizumab and risankizumab in patients with PsA who were biologic disease-modifying anti-rheumatic drug naïve (bDMARD naïve) or with previous inadequate response or intolerance to tumor necrosis factor inhibitors ...
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B. McInnes   +8 more
doaj   +2 more sources

Rapid response on facial psoriasis to bimekizumab: case series

Drugs in Context
Psoriasis is a chronic inflammatory disease that can affect any part of the body but, when it appears in certain areas, like the face, it can have a very significant psychological impact.
Nicoletta Bernardini, Annunziata Dattola, Giacomo Caldarola, Diego Orsini, Chiara Assorgi, Alessandra D’Amore, Giulia Maretti, Antonio Giovanni Richetta, Ersilia Tolino, Nevena Skroza, Concetta Potenza   +10 more
doaj   +2 more sources

Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies [PDF]

RMD Open
Objective To assess the impact of bimekizumab on physical functioning, sleep, work productivity and overall health-related quality of life (HRQoL) in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA) in the phase ...
Annelies Boonen, Atul Deodhar, Martin Rudwaleit, Lianne S Gensler, Karl Gaffney, Maureen Dubreuil, Victoria Navarro-Compán, Vanessa Taieb, Carmen Fleurinck, Ute Massow, Thomas Vaux, Michael F Mørup, Christine de la Loge   +12 more
doaj   +2 more sources

Bimekizumab as-needed dosing in patients with psoriasis: a case series [PDF]

Journal of Dermatological Treatment
Introduction Despite significant advances in psoriasis treatment, off-label dosing studies of psoriasis biologic therapies are limited.Materials and methods In this retrospective case series, medical records from 28 patients with moderate-to-severe ...
Carlota Abbad-Jaime De Aragón, Emilio Berna-Rico, Pedro Jaén, Andrew Blauvelt, Álvaro González-Cantero   +4 more
doaj   +2 more sources